
Please try another search
According to a Reuters report Wednesday, Novo Nordisk (NYSE:NVO) has enlisted Thermo Fisher Scientific (NYSE:TMO) as their second contract manufacturer for their highly sought-after weight-loss medication, Wegovy.
Sources told the publication that Thermo is responsible for filling the Wegovy injection pens at their factory located in Greenville, North Carolina.
The news has seen Thermo shares jump, hitting a high of $547.50 per share. The stock is currently trading at $542.20, up more than 2.8% in the session.
In May, Novo Chief Financial Officer Karsten Munk Knudsen revealed to Reuters that the company had signed up a second contract manufacturer in the US but did not disclose the identity of the company.
Novo is said to be rushing to increase the output of the drug to meet soaring demand in the US following production problems at a factory in Brussels, Belgium, operated by its first contract manufacturer, Catalent (NYSE:CTLT).
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.